IncellDx Inc (IncellDx) is a single-cell diagnostic company that develops transformative diagnostic and prognostic clinical patient information technologies. The company detects and monitors life-threatening viral diseases in the areas of cervical cancer, HIV and AIDS, hepatitis, and organ transplant rejection. Its products comprise HIV viral reservoirs probes, HIV tropism probes, HCV viral reservoirs probes, EBV viral reservoirs probes, E6 and E7 mRNA kits, E6 and E7 mRNA probes, fixative permeabilization reagents, core reagents, and HPV positive control and HPV negative control products. The company markets its products across Greece, Spain, China, India and the US. IncellDx is headquartered in Menlo Park, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company IncellDx Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
IncellDx Inc Company Overview
IncellDx Inc Company Snapshot
IncellDx Inc Pipeline Products and Ongoing Clinical Trials Overview
IncellDx Inc – Pipeline Analysis Overview
IncellDx Inc - Key Facts
IncellDx Inc - Major Products and Services
IncellDx Inc Pipeline Products by Development Stage
Feb 16, 2023: New data links modulation of key immune-related proteins to improvement of specific symptoms in long COVID
Sep 01, 2022: IncellDx receives CE-IVD marking for incellKINE Long Covid diagnostic test
Apr 19, 2022: i-Trac is the world’s first integrated health journey wearable and app for mental and physical wellness
Jan 11, 2022: Frontiers in Immunology publishes new study data from IncellDx supporting a model for understanding long COVID’s cause
Feb 03, 2021: IncellDx files patent for COVID long hauler index and active COVID-19 severity score
Jun 18, 2020: IncellDx files patent for CCL5/RANTES utility as a diagnostic, prognostic, and therapeutic biomarker in COVID-19 and other cytokine storm conditions
Jun 09, 2020: IncellDx’s Next Gen HPV/Cervical Cancer Assay (HPV OncoTect 3Dx) receives clinical approval from Costa Rican Ministry of Health
Mar 21, 2018: GIMDx and IncellDx Announce Acceleration of Chinese Commercialization of HPV OncoTect Kit
Jan 17, 2018: Premas, IncellDx Ink India Distribution Agreement
Mar 30, 2017: IncellDx Releases CE-IVD Quantitative Single Cell PD-L1 OncoTect iO Assay